FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of November 2026
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Klygefa (gefurulimab) approved in the US
16 November 2026
Klygefa
(gefurulimab) approved in the US for
the treatment of generalised myasthenia gravis (gMG) in adult
patients
Approval
supported by PREVAIL Phase
III results showing statistically significant and clinically
meaningful improvements in activities of daily living starting as
early as week one and sustained through one
year
First and only approved dual-binding nanobody C5 inhibitor in the
US, offering once-weekly subcutaneous self-administration via
autoinjector with rapid and sustained disease control
Alexion, AstraZeneca Rare Disease’s Klygefa (gefurulimab) has been approved in the US for the
treatment of generalised myasthenia gravis (gMG) in adult patients
who are anti-acetylcholine receptor (AChR) antibody
positive. Klygefa is the first and only dual-binding nanobody C5
inhibitor, offering once-weekly subcutaneous self-administration
via autoinjector.
The approval by the US Food and Drug Administration (FDA) was based
on positive
results from the pivotal
PREVAIL Phase III trial. Results from the trial showed that
Klygefa
met its primary endpoint,
demonstrating improvement from baseline in Myasthenia Gravis
Activities of Daily Living (MG-ADL) total score at week 26 compared
to placebo (treatment difference: -1.6 [95% CI: -2.4, -0.8],
p<0.0001). In addition to the week 26 prespecified results,
clinical improvement was observed as early as week
one.1
gMG is a rare autoimmune disorder characterised by reduced muscle
function and severe muscle weakness.2
In the US, an estimated 98,500 people
are diagnosed with gMG with 81,000 being
AChR-positive.3
Kelly Gwathmey, MD, associate professor in the Department of
Neurology’s Division of Neuromuscular Medicine at Columbia
University Vagelos College of Physicians and Surgeons; member of
the MGFA Medical & Scientific Advisory Council; and principal
investigator in the trial at Virginia Commonwealth University,
said: “gMG is a disease marked by unpredictability and
variability, for which early intervention and reliable disease
control are critical treatment goals. In the PREVAIL Phase III
trial, gefurulimab achieved both, delivering rapid and sustained
functional improvements with a once-weekly subcutaneous
self-administered injection. With this approval, patients in the US
gain a targeted treatment option that empowers greater autonomy
with the established efficacy of C5 complement
inhibition.”
Samantha Masterson, President & Chief Executive Officer,
Myasthenia Gravis Foundation of America (MGFA), said: “For
the gMG community, every new approved treatment represents more
than a clinical advance; it also represents choice. Because no two
patients experience gMG in the same way, expanding the range of
options available is fundamental to how we improve lives. The MGFA
welcomes this approval and the new possibilities it opens for those
who have been seeking more independence and greater control of
their treatment administration.”
Marc Dunoyer, Chief Executive Officer, Alexion, said: “The US
approval of Klygefa delivers a first-of-its-kind treatment for gMG
that offers the efficacy of C5 inhibition with the flexibility of
once-weekly subcutaneous self-administration via autoinjector. We
are proud to have discovered and developed this novel dual-binding
nanobody, and look forward to soon delivering this pioneering
innovation to adults with gMG in the US, offering the established
efficacy and safety of C5 inhibition with added
convenience.”
Klygefa was generally
well-tolerated, and the safety profile was consistent with previous
trials of C5 inhibitors eculizumab and ravulizumab in gMG. The
percentage of participants with treatment emergent adverse events
(TEAEs) was similar between those who received Klygefa and placebo, and most TEAEs observed were mild to
moderate in severity (grade 1 or 2). The most common TEAEs seen in
those receiving Klygefa were injection site reactions (12%), back pain
(8%) and vomiting (5%).1
The data from the PREVAIL trial were presented at the Myasthenia
Gravis Foundation of America (MGFA) Scientific Session during the
American Association of Neuromuscular & Electrodiagnostic
Medicine (AANEM) 2025 Annual Meeting and published in
JAMA
Neurology.1
Klygefa is approved in the
European Union (EU), Japan and other countries for certain adults
with gMG. Regulatory submissions based on the PREVAIL results are
under review in China and additional countries.
Notes
Generalised Myasthenia Gravis (gMG)
Generalised myasthenia gravis (gMG) is a rare autoimmune disorder
characterised by reduced muscle function and severe muscle
weakness.2
Eighty-five percent of people with gMG are AChR antibody-positive
meaning they produce specific antibodies (anti-AChR) that bind to
signal receptors at the neuromuscular junction (NMJ), the
connection point between nerve cells and the muscles they
control.4
This binding activates the complement
system, causing the immune system to attack the NMJ, leading to
inflammation and a breakdown in communication between the brain and
the muscles.5
gMG can occur at any age, but it most commonly begins for women
before the age of 40 and for men after the age of
60.6
Initial symptoms may include slurred
speech, double vision, droopy eyelids and lack of balance; these
can often lead to more severe symptoms as the disease progresses,
such as impaired swallowing, choking, extreme fatigue and
respiratory failure.7,8
PREVAIL (ALXN1720-MG-301)
PREVAIL (ALXN1720-MG-301) is a global, Phase III, randomised,
double-blind, placebo-controlled, parallel, multicentre study
evaluating the safety and efficacy of Klygefa (gefurulimab) in adults with generalised
myasthenia gravis (gMG). The trial enrolled 260 patients from 20
countries across North America, Europe, Asia and the Pacific
region. Participants were required to have a confirmed myasthenia
gravis diagnosis at least three months prior to the screening visit
with a positive serological test for autoantibodies against AChR
and Myasthenia Gravis Foundation of America Clinical Classification
Class II to IV at screening.9
Patients were randomised 1:1 to receive Klygefa or placebo for a total of 26 weeks in the
randomised controlled treatment period. Patients received a single
weight-based loading dose on Day 1, followed by regular
weight-based maintenance dosing beginning on Day 8 and once every
week thereafter. The primary endpoint of the change from baseline
in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total
score, a patient-reported scale that assesses patients’
abilities to perform daily activities, was assessed at week 26
along with multiple secondary endpoints evaluating improvement in
disease-related measures.9
Patients who completed the randomised controlled treatment period
were eligible to continue into an open-label extension period
evaluating the safety and efficacy of Klygefa, which is ongoing.9
Klygefa
(gefurulimab)
Klygefa (gefurulimab), a
complement C5 inhibitor, is a novel dual-binding nanobody optimised
for subcutaneous self-administration for the treatment of AChR-Ab+
gMG. The medication works by binding to the C5 protein in the
terminal complement cascade, a part of the body’s immune
system. When activated in an uncontrolled manner, the complement
cascade over-responds, leading the body to attack its own healthy
cells. Klygefa’s
concurrent binding to serum albumin
provides an extended half-life, enabling once-weekly
dosing.
Klygefa is approved in the
European Union (EU), Japan and other countries for certain adults
with gMG. Regulatory submissions based on the PREVAIL results are
under review in China and additional countries.
Alexion
Alexion, AstraZeneca Rare Disease, is focused on serving patients
and families affected by rare diseases and devastating conditions
through the discovery, development and delivery of life-changing
medicines. A pioneering leader in rare disease for more than three
decades, Alexion was the first to translate the complex biology of
the complement system into transformative medicines, and today it
continues to build a diversified pipeline across disease areas with
significant unmet need, using an array of innovative modalities. As
part of AstraZeneca, Alexion is continually expanding its global
geographic footprint to serve more rare disease patients around the
world. It is headquartered in Boston, US.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Disease, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca’s innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on Social Media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1.
Gwathmey KG, Saccà F, Howard JF Jr, et al.
Efficacy and safety of gefurulimab in generalized myasthenia
gravis: the PREVAIL phase 3 randomized clinical trial.
JAMA
Neurol. 2026 Jul
27.
2.
Jung-Plath W, et al. Assessment of myasthenia
gravis patients’ quality of life. The Journal of Neurosurgical
Nursing.
2023;12(2):74-83.
3.
AstraZeneca Data on File - Epidemiology estimates
are composed of a triangulation of different data sources including
Data Monitor, Decision Resources Group, Kantar Health, and internal
input. Available here.
Accessed November 2026.
4.
Lazaridis K, et al. Myasthenia gravis:
autoantibody specificities and their role in MG
management. Front
Neurol. 2020;11:596981.
5.
Huang YF, et al. Visualization and
characterization of complement activation in acetylcholine receptor
antibody seropositive myasthenia gravis. Muscle
Nerve.
2024.
6.
Cavanagh N, et al. Exploring the impairments and
allied health professional utilization in people with myasthenia
gravis: a cross-sectional study. J Clin
Neurosci.
2023;114:9-16.
7.
Catalin J, et al. Clinical presentation of
myasthenia gravis. Thymus. 2019.
8.
Farid ZR, et al. Factors affecting generalization
of ocular myasthenia gravis. Sriwijaya Journal of
Ophthalmology. 2020;3(2):48-54.
9.
ClinicalTrials.gov. Safety and efficacy of
ALXN1720 in adults with generalized myasthenia gravis. NCT
Identifier: NCT05556096. Available here.
Accessed November 2026.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date: 16 November 2026
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|